“…As in the cytoplasm, inhibiting protein folding in the ER is likely to have broad antiviral activity against the Mononegavirales due to their general use of this compartment for the generation of essential glycoproteins. Indeed, non-specific interference with protein folding in the ER by altering calcium levels or by blocking key glycosylation enzymes that prevent folding have been reported to block the maturation of VSV [107,114], SV5 [100], MeV [97], and EBOV [115]. In addition, compounds that inhibit multiple chaperones, including those present in the ER, such as Sorafenib, OSU-0312, or epigallocatechin gallate, can reduce the replication of EBOV, MeV, and MuV infection [98,103,104,116].…”